Abstract:Background: Advanced therapies are increasingly utilized to treat pulmonary embolism (PE). A unique data platform allows access to electronic health record data for comparison of the safety of PE therapies. Methods: All data from Truveta (Truveta, Inc) were analyzed (16 systems, 83,612,413 patients, 535,567 with PE). All patients treated with ultrasound-assisted catheter-directed thrombolysis (USCDT) (Boston Scientific) or mechanical thrombectomy (MT) (Inari Medical) for PE were identified. The primary analysis was based on index procedures performed from January 2009 to May 2023, and contemporary analysis on those performed from January 2018 to May 2023. Bleeding was assessed via direct laboratory analysis and transfusion administration documentation. International Society for Thrombosis and Hemostasis (ISTH) and Bleeding Academic Research Consortium (BARC) 3b definitions were recreated. Multiple logistic regression analysis of major bleeding was performed. In-hospital death and median length of stay were measured. Results: For the primary analysis, 2259 patients (N = 1577 USCDT, N = 682 MT) and for the contemporary analysis 1798 patients (N = 1137 USCDT, N = 661 MT) met the criteria. Incidence of hemoglobin reduction (>2 and >5 g/dL) and transfusions received were significantly higher among MT-treated patients in both analyses, as was ISTH and BARC 3b major bleeding (primary: ISTH MT 17.3% vs USCDT 12.4% P = .002; BARC 3b MT 15.4% vs USCDT 11.8% P = .019) (contemporary: ISTH MT 17.2% vs USCDT 11.0% P = .0002; BARC 3b MT 15.4% vs USCDT 10.6% P = .002). Regression analysis demonstrated that MT is associated with major bleeding. Median length of stay, all-cause 30-day readmission and in-hospital mortality were similar between groups. Intracranial hemorrhage was more common with MT. Conclusions: Major bleeding derived from direct laboratory and transfusion data occurred more frequently with MT vs USCDT. Intracranial hemorrhage was more common among MT-treated patients. In the absence of randomized data, these results provide guidance regarding the bleeding risk and safety of strategies for advanced PE therapy.

Evidence-Based Update on Transcatheter Therapies for Pulmonary Embolism

Acute Pulmonary Embolism: Evidence, Innovation, and Horizons

Cutting-Edge Techniques and Drugs for the Treatment of Pulmonary Embolism: Current Knowledge and Future Perspectives

Endovascular treatments of acute pulmonary embolism in the post-fibrinolytic era: an up-to-date review

Interventional therapies for pulmonary embolism

A Primer and Narrative Review of the Evolving Landscape

Novel Challenges and Therapeutic Options for Pulmonary Embolism and Deep Vein Thrombosis

Role of Transthoracic Lung Ultrasonography in the Diagnosis of Pulmonary Embolism: A Systematic Review and Meta-Analysis

Risk Stratification and Management of Intermediate- and High-Risk Pulmonary Embolism

Acute Pulmonary Embolus: The Next Frontier in Venous Thromboembolic Interventions

Pulmonary Embolism: An Update Based on the Revised AWMF-S2k Guideline

Multidisciplinary Approach to Pulmonary Embolism and the Role of the Pulmonary Embolism Response Team

Innovation in Catheter-Directed Therapy for Intermediate-High-Risk and High-Risk Pulmonary Embolism

Evolution of Pulmonary Embolism Response Teams in the United States: A Review of the Literature

Intensive Care Treatment of Pulmonary Embolism: An Update Based on the Revised AWMF S2k Guideline

Advances in Pulmonary Embolism Biomarkers

The Current Evidence of Pulmonary Embolism Response Teams and Their Role in Future

Anticoagulant Therapy in Patients Undergoing Acute Pulmonary Embolism Interventions

Interventional Therapies and Mechanical Circulatory Support for Acute Pulmonary Embolism

Risk Stratification and Management of Intermediate-Risk Acute Pulmonary Embolism

Modern Treatment of Pulmonary Embolism (USCDT vs MT): Results From a Real-World, Big Data Analysis (REAL-PE)